Microbix Biosystems Inc.
Microbix Biosystems Inc.
- Market cap
- $21.93M
Your view on MBXBF
Overview
What the company does, where it operates, and who runs it.
About Microbix Biosystems Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cameron L. Groome
- Headquarters
- 265 Watline Avenue, Mississauga, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cameron L. Groome
- Headquarters
- 265 Watline Avenue, Mississauga, ON, CA
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.
It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.
The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Microbix Biosystems Inc.. Starting points for Microbix Biosystems Inc.: EPS -$0.04, beta 0.38 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Microbix Biosystems Inc.. Microbix Biosystems Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Microbix Biosystems Inc.. Trailing twelve-month EPS for Microbix Biosystems Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2026 | This yearYear to Sep 2026 | Next yearYear to Sep 2027 |
|---|---|---|---|
| Average estimate | CAD 0.00 | −CAD 0.01 | CAD 0.01 |
| Lowest estimate | CAD 0.00 | −CAD 0.01 | CAD 0.01 |
| Highest estimate | CAD 0.00 | −CAD 0.01 | CAD 0.01 |
| Number of analysts | 0 | 1 | 1 |
| A year ago | −CAD 0.01 | −CAD 0.02 | — |
| Growth vs a year ago | +100.0% | +38.1% | — |
Revenue estimates
| Total | This quarterSep 2026 | This yearYear to Sep 2026 | Next yearYear to Sep 2027 |
|---|---|---|---|
| Average estimate | CAD 4.42M | CAD 16.16M | CAD 20.02M |
| Lowest estimate | CAD 4.42M | CAD 16.16M | CAD 20.02M |
| Highest estimate | CAD 4.42M | CAD 16.16M | CAD 20.02M |
| Number of analysts | 1 | 1 | 1 |
| A year ago | CAD 3.75M | CAD 18.61M | — |
| Growth vs a year ago | +17.7% | −13.2% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Microbix Biosystems Inc.. Microbix Biosystems Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AHGIFAlternate Health Corp. | Healthcare | Medical - Healthcare Information Services | $7,788 | ||
| BBIXFBonus BioGroup Ltd. | Healthcare | Biotechnology | $157.7M | ||
| CLYYFCelyad Oncology S.A. | Healthcare | Biotechnology | $6.7M | ||
| DTCFFDefence Therapeutics Inc. | Healthcare | Biotechnology | $22.9M | ||
| ELVAFEvolva Holding S.A. | Financial Services | Shell Companies | $7.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | Biotechnology | $18.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NTLAIntellia Therapeutics, Inc. | Healthcare | NASDAQ | $1.4B | ||
| NTRBNutriband Inc. | Healthcare | NASDAQ | $59.8M | ||
| NTRBWNutriband Inc. | Healthcare | NASDAQ | $76.8M | ||
| NTRRNeutra Corp. | Healthcare | OTC | $291,790 | ||
| NURPFNeuren Pharmaceuticals Limited | Healthcare | OTC | $1.1B | ||
| NUVBNuvation Bio Inc. | Healthcare | NYSE | $1.3B | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | ASX | — | ||
| NVAXNovavax, Inc. | Healthcare | NASDAQ | $1.2B | ||
| NVCTNuvectis Pharma, Inc. | Healthcare | NASDAQ | $666.8M | ||
| NWBONorthwest Biotherapeutics, Inc. | Healthcare | OTC | $359.4M | ||
| NWPHFNewron Pharmaceuticals S.p.A. | Healthcare | OTC | $239.5M | ||
| NXTCNextCure, Inc. | Healthcare | NASDAQ | $29.5M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Microbix Biosystems Inc.. Coverage tracks Microbix Biosystems Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Microbix Biosystems Inc.